Atlanta area investor & consultant: biotech, cryptos, title/mortgage securities. Advocate of alternatives to animal testing. Not giving investment advice.
@dayumm_daniel@Pharmdca You say you're on ret for 2 months and down 22 lbs. But did you not post a month ago that you were on it for 2 1/2 months and down 30 lbs ??? https://t.co/59amvjacOK
@Pharmdca@Bigpharmalover@bioinvestor24 I’ve been on Retatrutide ( Lilly’s phase 3 trial for triple antagonist weight loss) I gotta say it’s pretty wicked. Down 30 lbs in 2 1/2 months . Very little to no side effects . I’m worried retatrutide will be king
@justpavankumar Is there redundancy between $ABBV's amylin and $VKTX's Amylin DACRA? Does $LLY have no ability to get a best in class amylin to pair with their pipeline?
I like to think that $VKTX has good management, but, why have they been sitting on VK2809 for NASH/MASH for almost *2 years* since reporting good Ph2 results in June 2024?
Seems like total radio silence. I know it's not their top focus, but if it has value shouldn't they have monetized it?
50% drop in $RVPH this morning because FDA advised them to complete 2nd ph3 trial before submitting NDA; but I see the 2nd Ph3 trial was already planned, so could this news have been that unexpected?